Clik here to view.
Welcome to Blawg Review #260
The Genomics Law Report is pleased to host the 260th Blawg Review. For regular GLR readers who are unfamiliar with the Blawg Review concept, it’s the longest-running weekly recap of legal blog posts in...
View ArticleThe Unexpected Impact of Genetics on the Business World
Recent advances in genetic science are remarkable. In 2003 the first full human genome was sequenced after 13 years of work at a cost of over $3 billion. Today, the cost to sequence any individual’s...
View ArticleClik here to view.
WARF Reexamination Takes Another Bite Out of Biotech Patents
Two months ago, the Myriad gene patent litigation generated a slew of national and international coverage. We said, “Pigs Fly: Federal Court Invalidates Myriad’s Patent Claims.” “Is the DNA patent...
View ArticleClik here to view.
Betting on Bilski: The Supreme Court and Biotechnology Patents
There is a two-part question that we are frequently asked these days: “When is Bilski going to be decided and what’s the decision going to be?” The first part of that question is easy to answer....
View ArticleClik here to view.
Swine Soar Higher in Myriad Thanks to US Government’s Amicus Brief
This past March Judge Robert Sweet handed down an unexpected summary judgment ruling in the Myriad gene patent litigation (see: Pigs Fly: Federal Court Invalidates Myriad’s Patent Claims). Myriad...
View ArticleTwitter Roundup: FDA DTC Edition (and a new format)
Beginning this week, we are unveiling a new format for the Genomics Law Report’s regular Twitter Roundup. In addition to cataloging Dan’s @genomicslawyer tweets, we will also be offering short...
View ArticleClik here to view.
A Spectator’s Guide to the Myriad Oral Argument
On Monday at 10 a.m., the lawyers for both sides will argue the Myriad case (Association for Molecular Pathology v. USPTO) before a three-judge panel of the United States Court of Appeals for the...
View ArticleClik here to view.
News Roundup: Patent Reform Passes House, Human Provenance Project Pulled by UK
With so many developments at the intersection of genomics and the law, there is often a variety of interesting stories that, for one reason or another, don’t find their way into a full-length posting...
View ArticleClik here to view.
Pigs Return to Earth: Federal Circuit Reinstates Most—But Not All—of Myriad’s...
The Federal Circuit’s long-awaited decision (pdf) in Association for Molecular Pathology v. USPTO (the Myriad gene patent litigation) was issued this past Friday. As we were writing, with the economy...
View ArticleClik here to view.
Analyzing The America Invents Act
The America Invents Act (pdf) (AIA), which was signed into law by President Obama on Friday, September 16, 2011, represents the first major legislative adjustment to the U.S. patent system in decades...
View ArticleClik here to view.
Welcome to Blawg Review #260
The Genomics Law Report is pleased to host the 260th Blawg Review. For regular GLR readers who are unfamiliar with the Blawg Review concept, it’s the longest-running weekly recap of legal blog posts in...
View ArticleThe Unexpected Impact of Genetics on the Business World
Recent advances in genetic science are remarkable. In 2003 the first full human genome was sequenced after 13 years of work at a cost of over $3 billion. Today, the cost to sequence any individual’s...
View ArticleClik here to view.
WARF Reexamination Takes Another Bite Out of Biotech Patents
Two months ago, the Myriad gene patent litigation generated a slew of national and international coverage. We said, “Pigs Fly: Federal Court Invalidates Myriad’s Patent Claims.” “Is the DNA patent...
View ArticleClik here to view.
Betting on Bilski: The Supreme Court and Biotechnology Patents
There is a two-part question that we are frequently asked these days: “When is Bilski going to be decided and what’s the decision going to be?” The first part of that question is easy to answer....
View ArticleClik here to view.
Swine Soar Higher in Myriad Thanks to US Government’s Amicus Brief
This past March Judge Robert Sweet handed down an unexpected summary judgment ruling in the Myriad gene patent litigation (see: Pigs Fly: Federal Court Invalidates Myriad’s Patent Claims). Myriad...
View ArticleTwitter Roundup: FDA DTC Edition (and a new format)
Beginning this week, we are unveiling a new format for the Genomics Law Report’s regular Twitter Roundup. In addition to cataloging Dan’s @genomicslawyer tweets, we will also be offering short...
View ArticleClik here to view.
A Spectator’s Guide to the Myriad Oral Argument
On Monday at 10 a.m., the lawyers for both sides will argue the Myriad case (Association for Molecular Pathology v. USPTO) before a three-judge panel of the United States Court of Appeals for the...
View ArticleClik here to view.
News Roundup: Patent Reform Passes House, Human Provenance Project Pulled by UK
With so many developments at the intersection of genomics and the law, there is often a variety of interesting stories that, for one reason or another, don’t find their way into a full-length posting...
View ArticleClik here to view.
Pigs Return to Earth: Federal Circuit Reinstates Most—But Not All—of Myriad’s...
The Federal Circuit’s long-awaited decision (pdf) in Association for Molecular Pathology v. USPTO (the Myriad gene patent litigation) was issued this past Friday. As we were writing, with the economy...
View ArticleClik here to view.
Analyzing The America Invents Act
The America Invents Act (pdf) (AIA), which was signed into law by President Obama on Friday, September 16, 2011, represents the first major legislative adjustment to the U.S. patent system in decades...
View Article
